Introduction
From the knowledge gained from various prospective studies, the incidence of respiratory distress (RDS) can be reduced by giving the mother glucocorticoids. Today due to fear of the side effects of such therapy, there has been a reduction in the use of prophylaxis with corticoids. Different substances and methods have been proposed for induction of antenatal lung maturation including thyroid hormones, Intralipid®, ambroxol, carnitine, theophylline (aminophylline) and betamimetic agents.
Thyroid hormones
For a long time it has been known that there is a connection between lung maturity and thyroid gland metabolism [12] . Some authors found decreased Ts and T4 values in umbilical cord blood samples from infants who later developed RDS [1] , In 1974 in a study with MEINHOLD, we found a correlation between amniotic fluid lecithin and the reverse Ta level [11] .
Studies performed on rats, rabbits and lambs have shown that thyroxine stimulates the phospholipid production in the fetal lung, where Ts and T4 receptors can be found. Since the transfer of Ts and T4 through the placenta is very minimal, the thyroxine has to be given intra-amniotically or into the fetus.
In human beings intra-amniotic instillation of thyroxine should increase lung maturity and lower the number of cases of RDS [10] . In order to measure the effectiveness of surfactant stimulation with thyroxine, 22 pregnant patients with a gestational age of under 35 weeks were studied. The concentration of thyroxine and lecithin in amniotic fluid and in maternal and fetal serum were determined after giving an intra-amniotic dosage of 500 g levothyroxine [2] . The hormone determinations were performed radioimmunologically and the lecithin was determined enzymatically.
Groups were drawn up according to the interval between the instillation of T4 in the amniotic fluid and fresh normal amniotic fluid collected when the membranes ruptured at the start of labor. In this way a limit of 5 days was empirically created in 12 cases the interval was the same or less than 5 days (Group A), in the remaining 10 cases the time interval was more than 5 days (Group B).
Amniotic fluid:
The mean value of the T4 concentration rises in Group A 18 times as the control group. In Group B the concentration is not different from the original level (figure 1). The mean value of rTs after T4 injections into the amniotic fluid points to a significant increase which is about 13 times normal. In Group B no difference can be seen.
Umbilical cord blood:
While the T4 and rTs concentrations in Group A and B are significantly different, the T3 concentrations are similar in both groups (figure 2). Similar results to the increase in T4 in umbilical cord blood were reported by RIDDICK et al in 1979 [14] .
Maternal serum:
The concentrations of T4, Ta and rTs were measured before, 30 minutes after and 24 hours after T4 injections into the amniotic fluid (figure 3). No significant changes were to be seen in maternal blood. The results must be interpreted such that the T4 injection into the amniotic fluid leads to an increase of T4 in the fetal blood. This clearly demonstrates that the T4 injected into the amniotic fluid is absorbed by the fetus. However in the group where the interval between injection and delivery was more than 5 days, we observed that the T4 level had become normal again.
Thyroid hormones absorbed by the fetus will exercise their effect on various fetal organs. As an expression of the cardial effect of the thyroid hormones after thyroxine injection we found a moderate fetal tachycardia in 5 cases two days after the injection.
It seems that there is no paraplacental passage of the T4 injected into the maternal blood.
In addition to the hormone examination we also tested the lecithin concentrations in amniotic fluid before and after T4 injections; we observed a significant increase of the median values from 3.5 mg/100 ml to 5.2 mg/100 ml after injection. The mean value in Group A was 5.6 mg/100 ml and in Group B 4.3 mg/100 ml. The induction of surfactant production by means of thyroxine probably creates a reversible effect mechanism.
In this connection RDS diagnosed by neonatologists is important: While in our group about 8 cases of RDS were to be expected, this diagnosis had only been made in 2 cases.
Therapy with thyroid hormone is possibly mediated through TRH, which can be administered to the patient intravenously and affects the infant through the placenta [13] . This type of lung maturation induction is still only in the testing stage at the moment. There are suggestions that combined therapy with thyroid hormones and glucocorticoids has a marked effect on fetal lung maturity; however definite guidelines have not been drawn up [16] .
Too little is known at present about the side effects of treatment with thyroid hormones or their analogous. Changes in growth or cerebral dysfunctions due to hyperthyroidism are possible. The risks involved in giving thyroxine with regard to increase in oxygen output are not understood although this increase does not necessarily have to be the same in all organs. The question of increased oxygen output of T4 injection would be of particular importance when dealing with fetuses with respiratory placental insufficiency.
Intra-amniotic application of Intralipid®
OBERHEUSER and KLINK examined the possibility of stimulating surfactant formation by supplying a substrate of lecithin [6] . As the lecithins are supposedly not absorbed by the placenta, they have to be given intra-amniotically. They are able to prove in tests on rabbits, dwarf pigs and also on human subjects, that the lecithin is swallowed by the fetus and is absorbed in the intestine. The metabolism takes place in the liver. After resynthesis part of the lecithin is to be found in the pulmonary alveoli.
In the meantime the group has been able to prove the Intralipid® effects in tissue cultures of the human fetal lung, too.
On the basis of the mentioned observations they carried out intra-amniotic injection of Intralipid® in patients with premature labor between the 26th -36th week of gestation. They applied 60 ml Intralipid® in exchange for aspirated amniotic fluid which was used to determine the L/S ratio. In all cases there was no evidence of premature rupture of membranes.
The frequency and degree of RDS in premature babies with a birth weight under 2500 g during the past 7 years in the University Hospital of Lübeck were evaluated in order to assess the efficacy of Intralipid® therapy. Table I shows the frequency and degree of RDS in premature infants after Intralipid® application, corticosteroid therapy in the form of 2 50 mg Solu-Decortin® I.V. within the first 24 hours and cases without previous induction of fetal lung maturity.
Statistical significance of the efficacy of Intralipid® injection cannot be determined due to the small number of cases and the large difference in the individual groups. It should be pointed out, that no death was observed, and only one case with severe RDS was recorded. As far as mortality is concerned, corticosteroid therapy, as expected, is compared to untreated cases. Table I . Frequency and degree of RDS after Intralipid® injection, after corticosteroid therapy and without lung maturation promotion [6] . 
Ambroxol
Clinical studies and experiments on animals have been performed for years in order to prove the effect of ambroxol on lung maturation. The effect is supposed to be dependent upon stimulation of the secretory cells in the alveolar epithelium. This mechanical effect has not been definitely clarified.
Earlier clinical studies -some involving a smaller dosage than today -did not provide positive results [9] . In 1982 WALTER and coworkers, in a larger double-blind study, showed that in patients with a gestational age of 33 to 36 weeks, who had been given 1000 g ambroxol intravenously over a period of 5 days, the incidence of RDS was lower [17]. They did not find an effect before the 32nd week of gestation.
A German-Austrian multicenter double-blind study of 190 children examined the effects of betamethasone and ambroxol for antenatal pulmonary maturity induction between the 28th and 36th week of gestation. They showed that the same results were achieved with ambroxol as with betamethasone [15] . Ambroxol would have an advantage due to few long-term side effects. The disadvantage of the therapy is that it requires five days. It is not always possible to treat a patient effectively with tocolytic drugs for 5 days or to postpone a premature delivery.
intramitochondrial transport and regulation of the beta-oxydation of long chain fatty acids. The synthesis of palmitic acids, their insertion into mitochondria! phospholipids and also the formation of lecithin via methylation could be stimulated by carnitine. In animal experiments, LOHNIN-GER and coworkers were able to show that the combination of carnitine and betamethasone due to their different mechanisms, leads to a larger increase of phosphatidylcholin in the lung of the fetal rat than single dosages of the two substances [8] . Comparable results were found in the carnitine/thyroxin group.
Aminophylline
Animal studies of the effect of aminophylline on pulmonary maturity induction have been hopeful. HAJIGEORGIOU and coworkers have reported in a prospective study of a lessened incidence of RDS after treating mothers with aminophylline [5] . The effect is neither absolute, nor have the side effects been studied intensively. It is assumed that aminophylline increases the tissue content of cyclic AMP (cAMP) by inhibition of cAMP-phosphodiesterase. An increase in phospholipid synthesis takes place through the increased concentration of cAMP in the alveolar cells.
Carnitine
Carnitine is known to be an important factor for breaking down fatty acids in humans. With increased gestational age, a rise in the carnitine content was measured in the fetal lung of the rat. The carnitine dosage given to the pregnant rat caused a rise in the carnitine level in the fetal lung [7] . The suggestion that pulmonary maturity induction could be achieved with carnitine assumes that carnitine encourages surfactant formation by
Betasympathomimetic agents
Betasympathomimetic agents are used to inhibit uterine contractions. Retrospective studies have shown that when used for a short period they decrease the incidence of RDS [4] . Possibly these agents also produce changes in the cAMP content and increase adenylcyclase or increase the release of surfactant from the lamellar bodies. The importance of betasympathomimetics is dependent on the amount given and the duration of therapy and has not been clarified definitely [3] . Ambroxol: L'effet de l'ambroxol sur la maturation pulmonaire est suppose dependre d'une stimulation des cellules secretaires de repithelium alveolaire. Toutefois, cet effet mecanique n'a pas ete definitivement clarifie. En 1982 une etude en double aveugle plus importante a ete public; eile montre que chez les patientes avec un äge gestationnel de 33 ä 36 semaines, auxquelles on a injecte 1000 g d'ambroxol par voie intra-veineuse sur une periode de 5 jours, l'incidence du syndrome des membranes hyalines est plus faible. Neanmoins, on n'a pas trouve d'effet avant la 32e semaine de gestation. Carnitine: Avec l'elevation de l'äge gestationel, on a mesure une elevation de la teneur en carnitine dans le poumon foetal chez le rat et l'apport de carnitine ä la rate gravide entraine une elevation du taux de carnitine dasn le poumon foetal. Aminophylline: II a ete vu dans une etude prospective une minoration de l'incidence du syndrome de membranes hyalines apres traitement maternel par aminophylline. L'effet n'est pas certain d'une part et d'autre part les effects secondaires n'ont pas ete etudies de facon intensive.
Betamimetiques: Des etudes retrospectives ont montre que lorsqu'on les utilise pendant une courte periode, ils diminuent l'incidence du syndrome des membranes hyalines.
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